Integragen S.A [ALINT] vs Abivax SA [ABVX] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 17 vital metrics comparison: Integragen S.A. wins in 9 metrics, Abivax SA wins in 6 metrics, with 0 ties. Integragen S.A. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Integragen S.A. | Abivax SA | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -5.92 | -19.88 | Integragen S.A. |
| Price-to-Book Ratio | 0.57 | 16.56 | Integragen S.A. |
| Debt-to-Equity Ratio | 119.83 | 7.05 | Abivax SA |
| PEG Ratio | N/A | -30.74 | N/A |
| EV/EBITDA | 2.39 | -29.63 | Integragen S.A. |
| Profit Margin (TTM) | -23.43% | 0.00% | Abivax SA |
| Operating Margin (TTM) | -53.37% | -3,743.37% | Integragen S.A. |
| Return on Equity | -138.00% | -135.58% | Abivax SA |
| Return on Assets (TTM) | -23.72% | -38.95% | Integragen S.A. |
| Free Cash Flow (TTM) | N/A | $-161.27M | N/A |
| 1-Year Return | -69.49% | 2,047.73% | Abivax SA |
| Price-to-Sales Ratio (TTM) | 0.16 | 1,665.64 | Integragen S.A. |
| Enterprise Value | $402,530 | $7.26B | Abivax SA |
| EV/Revenue Ratio | 0.03 | 1,588.16 | Integragen S.A. |
| Revenue per Share (TTM) | $2 | $0 | Integragen S.A. |
| Earnings per Share (Diluted) | $-0.04 | $-4.83 | Integragen S.A. |
| Beta (Stock Volatility) | 0.39 | -0.10 | Abivax SA |
Integragen S.A. vs Abivax SA Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Integragen S.A. | -5.95% | 26.32% | 41.18% | 33.33% | 50.00% | 71.43% |
| Abivax SA | 12.92% | -36.61% | -28.82% | -25.31% | -26.24% | -38.04% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Integragen S.A. | -69.49% | -85.83% | -89.83% | -95.20% | -97.43% | -97.43% |
| Abivax SA | 2,047.73% | 517.65% | 305.72% | 1,019.45% | 447.83% | 447.83% |
Performance & Financial Health Analysis: Integragen S.A. vs Abivax SA
| Metric | ALINT | ABVX |
|---|---|---|
| Market Information | ||
| Market Cap | €1.11M | €7.61B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 5,766 | 104,525 |
| 90 Day Avg. Volume | 10,024 | 233,472 |
| Last Close | €0.24 | €71.25 |
| 52 Week Range | €0.12 - €0.57 | €5.12 - €132.00 |
| % from 52W High | -58.42% | -46.02% |
| All-Time High | €10.37 (Feb 17, 2014) | €132.00 (Jan 12, 2026) |
| % from All-Time High | -97.69% | -46.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.40% | -0.55% |
| Quarterly Earnings Growth | N/A | N/A |
| Financial Health | ||
| Profit Margin (TTM) | -0.23% | 0.00% |
| Operating Margin (TTM) | -0.53% | -37.43% |
| Return on Equity (TTM) | -1.38% | -1.36% |
| Debt to Equity (MRQ) | 119.83 | 7.05 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.29 | €5.80 |
| Cash per Share (MRQ) | N/A | €6.70 |
| Operating Cash Flow (TTM) | N/A | €-161,128,992 |
| Levered Free Cash Flow (TTM) | €-171,399 | €-118,316,624 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Integragen S.A. vs Abivax SA
| Metric | ALINT (Apr 24, 2026) | ABVX (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -5.92 | -19.88 |
| Forward P/E | N/A | -30.74 |
| PEG Ratio | N/A | -30.74 |
| Price to Sales (TTM) | 0.16 | 1,665.64 |
| Price to Book (MRQ) | 0.57 | 16.56 |
| Market Capitalization | ||
| Market Capitalization | €1.11M | €7.61B |
| Enterprise Value | €402,530 | €7.26B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.03 | 1,588.16 |
| Enterprise to EBITDA | 2.39 | -29.63 |
| Risk & Other Metrics | ||
| Beta | 0.39 | -0.10 |
| Book Value per Share (MRQ) | €0.29 | €5.80 |
Financial Statements Comparison: Integragen S.A. vs Abivax SA
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | ALINT (2023) | ABVX (2025) |
|---|---|---|
| Revenue/Sales | 12.54M | 0 |
| Cost of Goods Sold | 7.52M | N/A |
| COGS % of Revenue | 60.0% | - |
| Gross Profit | 5.02M | N/A |
| Gross Margin | 40.0% | - |
| Research & Development | N/A | 177.76M |
| Operating Income (EBIT) | -117,608 | -246.06M |
| Operating Margin | -0.9% | - |
| EBITDA | 168,396 | -268.99M |
| EBITDA Margin | 1.3% | - |
| Pre-Tax Income | -259,080 | -330.25M |
| Pre-Tax Income % of Revenue | -2.1% | - |
| Income Tax | -87,682 | 5.85M |
| Income Tax % of Revenue | -0.7% | - |
| Net Income (Profit) | -171,398 | -336.10M |
| Profit Margin | -1.4% | - |
Balance Sheet & Liquidity Metrics
| Metric | ALINT (2023) | ABVX (2025) |
|---|---|---|
| Cash & Equivalents | 1.83M | 516.69M |
| Total Current Assets | 7.68M | 551.24M |
| Total Current Assets % of Revenue | 61.3% | - |
| Total Current Liabilities | 5.16M | 63.02M |
| Total Current Liabilities % of Revenue | 41.1% | - |
| Long-Term Debt | 642,280 | 554,000 |
| Long-Term Debt % of Revenue | 5.1% | - |
| Total Shareholders Equity | 2.01M | 455.21M |
| Retained Earnings | -1.35M | -738.48M |
| Retained Earnings % of Revenue | -10.8% | - |
| Property, Plant & Equipment | 1.54M | 463,000 |
Cash Flow Statement Comparison
| Metric | ALINT (2023) | ABVX (2025) |
|---|---|---|
| Operating Cash Flow | N/A | -270.21M |
| Operating Cash Flow % of Revenue | 0.0% | - |
| Capital Expenditures | N/A | -142,000 |
| Free Cash Flow | N/A | -161.27M |
| FCF Margin | 0.0% | - |
| Debt Repayment | N/A | -59.53M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ALINT | ABVX |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 6.62M | 78.54M |
| Float Shares | N/A | 64.14M |
| % Held by Insiders | 65.90% | 1.05% |
| % Held by Institutions | 0.00% | 45.76% |
| % Held by Public | 34.10% | 53.19% |
Dividend Analysis & Yield Comparison: Integragen S.A. vs Abivax SA
| Metric | ALINT | ABVX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |